A c c e p t e d M a n u s c r i p t
A c c e p t e d M a n u s c r i p t meningococcal serogroup W (MenW) predominated [36] , respectively. The emergence of MenW and MenY was evident in some countries worldwide [11, 14, 16, 29, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] .
Genomic alterations and epidemic potential of Neisseria meningitidis
The epidemic potential of a particular Nm strain may be increased by genomic alterations that infer antigenic shifts, metabolic shifts, and resistance to antibiotics [42, 43, 51, 54, 55, 63] . Further, within the cc11 population structure, MenB and MenC cc11 isolates were highly interspersed, suggesting multiple capsule switch events [37, 62] .
A genetically-altered ST-11 Nm strain has recently emerged as a cause of urethritis in males, with no reported differences in clinical presentation compared with gonococcal cases [60, 64] . Adaptation to the genitourinary niche was thought to be due, in part, to horizontal gene transfer of in-frame norB-aniA between Neisseria gonorrhoeae (Ng) and Nm [60, 64] . The loss of the ability to express a capsule was a further gonococcal trait that was caused by the deletion of some capsular genes.
Gain of aniA function has also been described in closely related MenC cc11 isolates from IMD cases among men who have sex with men (MSM) [65] .
A c c e p t e d M a n u s c r i p t
Epidemiology of recent meningococcal disease outbreaks
The magnitude, and subsequent societal and economic burden, of Nm outbreaks is often influenced by country/regional population structures, diagnostic capacity of healthcare systems and outbreak response (vaccination/prophylaxis). In the U.S.A., there have been numerous university outbreaks [12, [66] [67] [68] [69] [70] ; MenB predominated, with MenC more commonly seen in community-based outbreaks. Examples of university outbreaks between 2008 and 2017 involving MenB include Ohio University (2008) (2009) (2010) [70] , Princeton University (2013) (2014) [67, 68] , and Rutgers University [69] . In Africa, the high incidence of IMD was thought to be due to the dry season and start of the Harmattan (dry and sandy east wind) in sub-Saharan Africa, which favors colonization and transmission of Nm in the pharynx [6] . Historically, >80% of Nm outbreaks in the meningitis belt were caused by MenA [6] . As noted previously, MenA IMD cases reached 100 cases per 100,000 population in sub-Saharan Africa before the introduction of the MenA-TT conjugate vaccine immunization program [22] . By 2017, MenA had significantly decreased, MenW was relatively stable and [33, 34, 72] . Genomic analysis revealed that the strain was not genetically related to any MenC strains previously identified in Africa [33] . In April 2017, 31 IMD cases were reported, including 13 deaths, following attendance at the funeral of a religious leader in Liberia [73] . The outbreak was associated with atypical symptoms (diarrhea, vomiting and mental confusion) and metagenomic analysis revealed the presence of a strain with 91-98% similarity to ST-10217 in 6 of the 10 specimens analyzed, the remaining 4 specimens were inconclusive [73, 74] . This strain appears to be evolving and likely has epidemic potential [75] . Outbreaks have also been reported among military personnel. Indeed, the incidence of IMD is higher among soldiers in Korea than the national average, with 2.2 cases per 100,000 persons reported per year [76] . The novel serogroup C cc4821 emerged in China in 2003 and was responsible for the outbreaks in Anhui in China from 2003 to 2005 and has rapidly spread to most provinces of China, and there was also evidence of capsular switching between A c c e p t e d M a n u s c r i p t MenC and MenB [77, 78] . Continued epidemiological and sentinel surveillance of IMD could help determine the epidemic potential of Nm sublineages to inform future prevention strategies.
Review of current global meningococcal disease prevention and control strategies
There are marked differences in global prevention strategies, in terms of vaccination and antimicrobial prophylaxis. There are three types of vaccination: (i) polysaccharide; (ii) conjugate; and (iii) protein. In brief, polysaccharide vaccines are composed of pure bacterial cell wall polysaccharides, whereas conjugate vaccines are made by covalently bonding an antigen to an immunogenic carrier protein (e.g. tetanus toxoid, diphtheria toxoid or diphtheria toxoid variant CRM197) to enhance and maintain immunological B-cell memory [79] . This is particularly crucial for individual protection against IMD due to the generally short incubation period. Other advantages of conjugate vaccines over polysaccharide vaccines include the ability to impart herd protection by preventing acquisition of meningococci nasopharyngeal carriage among vaccinees [80] (see section 3.3.1), and lack of hypo-responsiveness with repeated dosing [7, 79, 81, 82] . Several conjugate vaccines are available worldwide [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] , with availability and licenced age differing by country. In contrast, protein-based vaccines include toxoids (inactivated bacterial toxin) and subunit or subvirion products, and are used when the use of a polysaccharide or conjugate is not possible (see section 3.3.2).
Some countries provide vaccination via National Immunisation Programmes (NIPs) and others provide vaccinations to high-risk populations (e.g. conjugate MenACWY in India) or for outbreak control only (e.g. MenB vaccine in Canada;
polysaccharide MenA and MenAC vaccines in Russia; polysaccharide vaccines in the African meningitis belt). The optimal approach is to include vaccination via NIPs to maximize coverage; however, this decision is often determined by costeffectiveness analyses [7] . A number of factors influence cost-effectiveness, including variables to incorporate, how to capture benefits and uncertainty, comparators, time-period and how to value items in the future. In some countries where vaccines are not provided free of charge, patients may pay for vaccines A c c e p t e d M a n u s c r i p t through the private healthcare sector. The prevailing factor for vaccination recommendations is the country-and serogroup-specific incidence of Nm by age group, highlighting the importance of continual surveillance to ensure vaccinations are available to those most in need in a timely manner. Conjugate vaccines, especially MenA, MenC and MenACWY, are used in many countries, except Northern Africa, Middle East and China where polysaccharides are used [6, 7, 47] . c c e p t e d M a n u s c r i p t conjugate vaccine at one university, a cross-sectional study showed that carriage of MenW increased substantially in first-year university students [100] . Additionally, the introduction of a monovalent MenA conjugate vaccine in Africa successfully reduced invasive disease and carriage rates by inducing direct and indirect (herd) protection, respectively [101] [102] [103] [104] . As mentioned previously, multivalent vaccines are being used more frequently with the aim of providing broader protection against IMD than monovalent vaccines. However, it is important to acknowledge that we still need more evidence to understand the true impact of multivalent conjugate vaccines against other serogroups.
Importance of MenB protein vaccines
Polysaccharide-based MenB vaccines do not exist. The alpha-2 linked polysialic acid of MenB is identical to that found on the surface of human neuronal cells, and thus, such vaccines would be poorly immunogenic and could potentially evoke an autoimmune response [105] . The approach was therefore to identify non-capsular antigens that are surface-exposed, conserved and can induce serum bactericidal antibodies. Outer membrane vesicle (OMV) vaccines were used in countries such as Norway, Cuba, Brazil, Chile, France, to control clonal MenB outbreaks in the 1980s, and also in New Zealand from 2004 to 2008 [106] . OMV vaccinations are still used in Cuba; they can provide protection when an IMD outbreak shares similar (not necessarily identical) PorA to that included in the vaccine [107] . Following the publication of the first meningococcal genome, reverse vaccinology was used to develop a vaccine comprising 3 primary recombinant antigens: (i) factor H-binding protein (fHbp); (ii) Neisserial adhesin A (NadA), and (iii) Neisseria Heparin-Binding Antigen (NHBA). In addition, it includes the OMV expressing PorA from the New Zealand strain, PorA P1.4 [108] [109] [110] . Since the introduction of the 4CMenB vaccine (Bexsero®) in 2015 in the U.K., 3 million doses have been administered and there has been a significant decline in the number of MenB cases among infants and toddlers [111] . A reported 2-dose vaccine effectiveness of 82.9% (95% CI 24.1─95.2) was reported against all MenB cases during the first 10 months of the program [111] . This was equivalent to a vaccine effectiveness of 94.2% against the highest predicted MenB strain coverage of 88% [111] . Current published data suggest that the 4CMenB vaccine has limited, if any, effect on the carriage of MenB A c c e p t e d M a n u s c r i p t [112] . Although the 4CMenB vaccine is reactogenic [113] , recent surveillance data do not support initial concerns with respect to increased risk of Kawasaki disease and seizures [114] . The 4CMenB vaccine has the potential to offer protection against meningococci belonging to other serogroups. Interestingly, infants that received the 4CMenB vaccine showed serum bactericidal antibody activity against the hypervirulent MenW ST-11 strain [115] , which is in line with the observed reduction in MenW cases among infants [116] . The Cuban OMV meningococcal BC vaccine (VA-MENGOC-BC®) has been used effectively in Cuba, and other Latin American countries [117, 118] , to control MenB disease [119] [120] [121] [122] [123] [124] [125] . Over 30 years, ~60 million doses of the Cuban OMV vaccine have been administered demonstrating a good safety and tolerability profile with a significant decrease in the incidence of IMD postvaccination [117, 118, 120] .
Given that Nm and Ng belong to the same genus, there are considerable structural similarities between the PorB protein found in Nm and Ng [126] . Further, the genes encoding fHbp and NHBA may also be found, and the corresponding proteins expressed, in Ng [127] ; although, fHbp is not surface-expressed in Ng [128] , and there are differences in the nucleotide and amino acid sequences between the 2 species [127] . Data, albeit limited, showed that meningococcal recombinant protein and OMV-based vaccines may provide protection against Ng in Canada and Cuba More in-depth analyses are ongoing to fully establish the nature of the relationship between the 4CMenB vaccine and Ng infection rate.
New approaches for vaccination strategies
The use of additional multivalent polysaccharide vaccines, as well as concomitant administration of multivalent vaccines with protein-based vaccines, to provide broader protection against IMD, are being considered and actively researched.
Evidence to date does not indicate any major safety signals for the multivalent MenACWY vaccines; however, there was a significant association between Bell's palsy and MenACWY-CRM when administered concomitantly with other vaccines.
Further, there was no association when the vaccine was administered alone [132] , thus highlighting the need for further investigations. The immunogenicity of co-A c c e p t e d M a n u s c r i p t administration of MenC-CRM and 4CMenB has also been studied with no immediate safety or effectiveness concerns [133] . New multivalent vaccines are being developed, including a pentavalent MenACWYX vaccine for Africa, which is currently being studied in clinical trials.
Use of meningococcal modeling in outbreaks and persistence of vaccine protection
A useful tool for informing IMD control strategies is transmission modeling, which can be used to predict IMD epidemiology, including the impact of proposed vaccination programs. Models should ideally incorporate data from disease surveillance, carriage studies and sero-epidemiology. As models are, by definition, simplifications of real world scenarios, they should be considered an additional, rather than a definitive, tool for decision making. Nevertheless, they have been used to inform vaccination programs. For example, modeling for the conjugate MenC vaccine in the U.K.
showed the significant decline in IMD cases when herd immunity was taken into consideration [134] . Modeling of PsA-TT used an age-structured transmission dynamic model to capture key epidemiological features of MenA in the African meningitis belt, including periodic epidemics, seasonality, varying sizes of epidemics, variable risk of disease age, carriage by age, immunity from carriage, and transmission between asymptomatic carriers [135] . Ultimately, the model highlighted the importance of the introduction of the vaccine into routine Extended Program on Immunization (EPI) or periodic mass vaccination in 1-4 year olds to avoid resurgence of MenA approximately 10-20 years after the initial mass campaign in 1-29 year olds [135] . Additionally, modeling for the introduction of the 4CMenB vaccine into the U.K. suggested that, if herd effects are assumed, long-term protection would be expected by vaccinating adolescents [136] . However, in the absence of herd effects, vaccination during infancy would be preferable, and since herd effects for meningococcal protein-based vaccines are unclear, this debate is ongoing [136] .
IMD modeling may be used to better understand the importance of particular assumptions, such as the persistence of protection of a vaccine, which can determine the need for, and timing of, booster vaccinations. For example, if the duration of protection is short (e.g. 5 years), booster vaccinations in those immunized at younger ages may be warranted to prevent resurgence. In fact, the A c c e p t e d M a n u s c r i p t
aforementioned PsA-TT model demonstrated that resurgence of MenA occurs earlier and with higher incidence if persistence is assumed to be 5 rather than 10 years [135] . Strategies such as catch-up campaigns and the routine immunization of older children could be considered if the duration of protection is known to be short.
Due to low incidence of IMD, it is not feasible to conduct efficacy studies for the licensure of meningococcal conjugate vaccines. These vaccines have been licensed on the basis of safety and immunogenicity data. This therefore requires surrogates of protection. Surrogates of protection, which are required for IMD modeling, are unknown for MenA. The use of human complement serum bactericidal assay (hSBA) may not be an appropriate correlate of protection for MenA and utilization of different MenA strains in rabbit complement serum bactericidal assay (rSBA) yield different lengths of protection [137] . Based on serogroup A-specific immunoglobulin G (IgG), a booster campaign would be required after 3 years for children aged 1─4 years following the PsA-TT campaign [138] . In contrast, a booster campaign would be required after 8 years for children aged 1─4 years following the PsA-TT campaign based on strain, A3125, and antibody persistence remains high, even 5 years following primary vaccination based on strain F8238 [139] . As such, further understanding of correlates of protection is needed.
Emergence of antibiotic resistance
Increased use of antibiotics worldwide for various bacterial infections has had a detrimental impact on antimicrobial resistance in bacteria. Nm is still susceptible to most antibiotics that are used for treatment and prophylaxis of IMD; however, the incidence of strains with reduced susceptibility to penicillin (as indicated by increased minimum inhibitory concentrations [MIC] towards the standardised breakpoint of nonsusceptibility) is increasing worldwide [140] . Non-susceptibility (or resistance) to penicillin arises from modifications in bacterial penicillin-binding proteins (PBPs); enzymes that are involved in peptidoglycan biosynthesis, which bind to penicillin and other beta-lactam antibiotics [140] . Alterations in the PBP2 protein encoded by the penA gene led to modifications of the bacteria's peptidoglycan structure, as well as a 10-fold reduction in its affinity for penicillin [141] , thereby reducing its susceptibility to the agent [140, 142] . Alterations of the penA gene most likely occurred through A c c e p t e d M a n u s c r i p t horizontal gene transfer from other species of the genus Neisseria (Neisseria perflava, Neisseria mucosa and Neisseria cinerea), producing a penA allele that has a mosaic structure. Of concern, isolates harbouring the allele penA327 showing reduced susceptibly to penicillin and third-generation cephalosporins were identified in 2012 [141] . The allele was found to originate from Ng [141] . The penA1C allele is currently only found in Ng, but carries a high level of resistance to penicillin and thirdgeneration cephalosporins. penA1C differs from penA327 by only 1 nucleotide, thus there is a risk that isolates with antibiotic resistance (rather than reduced susceptibility) may emerge in the future. Encouragingly, isolates resistant to rifampicin and ciprofloxacin are rare and heterogeneous [143] . Resistance to rifampicin arises from alterations in the rpoB gene, which lead to marked increases in the MIC of the isolates (>1.0 mg/L) [143] . Isolates that harbour a modified rpoB gene are rare and have only been identified in Europe [143] , but they remain a concern, especially in countries that use rifampicin as first-line antibiotic for prophylaxis. Ciprofloxacin resistance involves mutations in the gyrA gene [144] .
Isolates resistant to ciprofloxacin have been identified in France, India, Italy, Spain, and Sweden, and in 2009, an outbreak of resistant isolates was reported in the U.S.A. [144, 145] . Ciprofloxacin-resistant isolates have also been reported in Argentina and, in China, more than 70% of Nm strains are non-susceptible [46, 146] . Different Nm strains in China have shown non-susceptibility to ciprofloxacin [146] , as well as nalidixic acid [6] . Specifically, molecular profiling indicated a high prevalence of Nm quinolone non-susceptibility in Shanghai, which was associated with hypervirulent IMD lineages cc4821 and cc5, giving rise to 2 quinolone-resistant strains; cc4821-R1-C/B and cc5-R14-A [147] . Further, the MIC values of several antibiotics used in China to treat Nm have increased, and some ciprofloxacin-resistant strains obtained from healthy carriers possessed identical gyrA sequences to those obtained from individuals with IMD [146] . Global antibiotic resistance surveillance is therefore warranted to monitor changes in antibiotic susceptibility of Nm and to ensure IMD cases, including epidemics, are treated effectively.
IMD in high-risk groups
Country or region-specific immunization programs generally target populations considered most at risk of IMD or carriage. The incidence of IMD is highest among have a markedly increased risk for IMD. There is varied guidance on the use of antibiotic prophylaxis in such patients [12, 155] . MSM are also considered a high-risk group [154] , with a high incidence of MenC in both outbreak and non-outbreak settings. The cc11 strain was responsible for IMD outbreaks among MSM [156] , and HIV infection is likely responsible for most of the increased risk among MSM.
Following genomic analysis of the new clone of MenC identified in MSM, the strain was found to have acquired the capacity to spread via sexual transmission, as well as via respiratory droplets [65] . Additionally, numerous laboratory-acquired IMD cases have occurred, with half of cases resulting in death [157] . As such, it is also important to offer laboratory workers meningococcal vaccines and to ensure all safety procedures are followed.
There has been an increased incidence of IMD during some mass gatherings. gathering as a high concentration of people, at a specific location, for a specific purpose, over a set period of time, which has the potential to strain the planning and response resources of the country or community; however, the WHO does not currently recommend routine immunizations for mass gatherings, other than the Hajj and Umrah. Sports events (e.g. the Olympics), music festivals, high-profile funerals and military camps may also be rated as mass gatherings, but reports on subsequent IMD are scarce [168] . Irrespective of the definition, there are wider considerations regarding the association of IMD clusters within international mass gatherings, including markers of known risk factors, increased carriage/disease incidence, viral illness, close living, close contact, sharing food/drink, and air travel.
Global initiatives for IMD prevention
Despite meningitis and neonatal sepsis (which is almost indistinguishable from meningitis in neonates) together being the second biggest infectious killer of children however, it was emphasized that further analyses were needed. Finally, transmission models were highlighted as a useful tool to predict MD epidemiology and support control strategies, including the need for, and timing of, booster vaccinations.
However, the GMI cautioned that models were simplifications of real world scenarios so should be considered as an additional, rather than definitive, tool for decision making.
Although the GMI affirmed that Nm was susceptible to the antibiotics that were currently used for treatment and prophylaxis of IMD, it was cautioned that there was evidence that reduced susceptibility to antibiotics is increasing worldwide [140, 143] . Antibiotics are undoubtedly one of the most important tools used in the continue to lower IMD-related morbidity and mortality.
Summary
Based upon the data presented, it is clear that the epidemiology of IMD is constantly evolving, highlighting the need for surveillance and policies for prevention and control. Increasing application of genomic analyses worldwide has accelerated knowledge around the local evolution of all hyper-virulent Nm lineages, including the prophylaxis of IMD, reduced susceptibility to antibiotics continues to be a concern.
As such, global antibiotic resistance surveillance is recommended. Both the MRF and WHO have initiatives in development, including the development of a new task force and roadmap for meningitis to 2030.
Expert commentary
IMD is an important health concern with outbreaks occurring in many areas of the world, particularly in low-to middle-income countries where morbidity and mortality rates remain high. MenB and MenC remain a major cause of IMD worldwide; however, MenA, MenW, MenX and MenY, predominate in a number of different countries. In order to reduce the global incidence of IMD, it is imperative that countries and health organizations continually learn from the experiences and effective strategies implemented by other countries. Of note, the induction of herd protection following the implementation of conjugate vaccines into the NIP together with catch-up campaigns, as well as the observed potential for protein-based vaccines to offer protection against multiple serogroups (e.g. 4CMenB may protect against MenB and MenW) and Ng (e.g. protein -and OMV-based vaccines may provide protection against Ng in Canada and Cuba, respectively).
Currently, vaccines and antimicrobial prophylaxis are the mainstays of IMD prevention and have significantly reduced the incidence of IMD in many countries worldwide. To continue to reduce the incidence levels of IMD, there are a number of key issues that need to be addressed. Evidence gathered to date regarding the ability of Nm to adapt genetically, implies that new hyper-virulent strains may emerge.
Further, the imminent emergence of an antibiotic resistant strain of Nm is a valid and growing concern. As antibiotics are undoubtedly one of the most important tools used in the prophylaxis and treatment of IMD, an antibiotic-resistant strain could cause a substantial setback in the progress of the global management of IMD.
Ongoing vigilance and genomic analyses will ensure the prompt determination of the epidemic potential of Nm strains, to inform the rapid development and implementation of appropriate control strategies. At every opportunity, lessons should continue to be learned from the emergence of new strains, and the spread of other hypervirulent strains to increase knowledge on the evolution of such strains.
Moreover, global antibiotic resistance surveillance is imperative to ensure the continued efficacy of all IMD treatments.
Many steps are being taken to prevent outbreaks of IMD; however, outbreaks still occur and therefore continued efforts are needed. The observed increase in the incidence of IMD following some mass gatherings and other highly-attended events (e.g. sports fixtures and music festivals) highlights the need to target such events to help control the international spread of IMD. As a first step, revisiting the definition of mass gathering may prompt initiation of preventative measures for IMD to help mitigate the risk of international spread. Additionally, the targeted immunization of high-risk patient populations may also prevent IMD. Of course, achieving and sustaining IMD protection worldwide will be challenging given diverse standards in IMD management; however, continued country-and regional-specific efforts that underpin the GMI ethos for international cooperation will help drive an overall reduction in the incidence of IMD.
Five-year view
In the next 5 years, the epidemiology of IMD will most likely continue to vary both geographically and temporally due to many competing factors. With the 
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